Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or clinical decision-making. However, concerns over the credibility of real-world evidence studies have led to calls for more transparency on the design and conduct of RWE studies.
A joint task force between ISPE and ISPOR created a harmonized protocol template for RWE studies that evaluate a treatment effect and are intended to inform decision-making. The HARPER template provides clarity, structure, and a common denominator regarding the level of operational detail, context, and rationale necessary in a protocol.
HARPER = HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects
Link: https://lnkd.in/erkyU2iT
Four protocol templates were identified for RWE studies:
1. The European Medicines Agency’s (EMA) Guideline on Good Pharmacovigilance Practices (GVP) Module VIII – post-authorizations safety studies (PASS) template,
2. ISPE’s guidelines for good pharmacoepidemiology practice (ISPE GPP) section on protocol development,
3. The National Evaluation System for health Technology (NEST) protocol guidance, and
4. The Structured Template and Reporting Tool for Real World Evidence (STaRT-RWE).
The HARPER protocol contains nine sections, including a title page, abstract, and a table for amendments and updates. Each section includes structured free text, a structured table, or a figure, and a free-text section to lay out context and rationale for scientific choices.
The study design diagram shows the context and rationale for the study setting, time 0 (index date), inclusion criteria, exclusion criteria, variables, exposure, outcome, follow up, covariates, sensitivity analyses, data sources, metadata, and software used in the study.
The data sources section includes a free text component followed by a structured table for specifying data sources. The data sources section can also include a detailed evaluation of the fitness-for-purpose of data source options.
Overall, the HARPER framework is a valuable resource for researchers and clinicians who are planning or conducting RWE studies. The framework can help to ensure that protocols are well-designed and will produce high-quality evidence.
Share this story...
Real World Evidence (RWE) 101 – NICE Real World Evidence Framework
RWE 101 - NICE Real World Evidence Framework The UK's National Institute for Health and Care Excellence (NICE) has developed a Real World Evidence (RWE) Framework to help evaluate [...]
Real World Evidence (RWE) 101 – The Role of RWE in Health Technology Assessments (HTAs)
RWE 101 - The Role of RWE in Health Technology Assessments (HTAs) Real-world evidence (RWE) is becoming increasingly important in the context of health technology assessment (HTA), which is [...]
Real World Evidence (RWE) 101 – Verifying the Source of Data (Not to be Confused with Source Data Verification…Yup! Confusing!)
RWE 101 - Verifying the Source of Data (Not to be Confused with Source Data Verification...Yup! Confusing!) Verifying the source of data is critical in the context of real [...]
Real World Evidence (RWE) 101 – Challenges in RWE Generation (Regulatory Grade RWE?)
RWE 101 - Challenges in RWE Generation (Regulatory Grade RWE?) Real-world evidence (RWE) refers to data derived from real-world sources such as electronic health records, claims data, and patient-generated [...]
Real World Evidence (RWE) 101 – Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations
RWE 101 - Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations Real-world evidence (RWE) studies include observational studies that uses data collected in real-world settings to [...]
Real World Evidence (RWE) 101 – Acknowledgement of the Limitations of Clinical Trials and RWE Studies
RWE 101 - Acknowledgement of the Limitations of Clinical Trials and RWE Studies Clinical trials are experiments designed to test the safety and efficacy of new treatments or [...]







